Biotech entrepreneur and former NVIDIA product lead joins to help foster growth in digital biology and health
Oxford Science Enterprises (OSE) has appointed Harry Clifford as Entrepreneur-in-Residence (EIR) within its Health Tech team, bringing with him a wealth of experience across biotechnology, AI, venture-building, and cutting-edge academic research.
Harry was previously part of the healthcare team at NVIDIA, where he led product development for their Digital Biology frameworks and Software Development Kits (SDKs). His work included technologies such as NVIDIA Parabricks, for high-accuracy accelerated genomics analysis, and BioNeMo Framework, for advancing computational drug discovery with AI.
He also co-founded Cambridge Cancer Genomics (CCG.ai), a Y-Combinator and Merck-Accelerator-backed startup dedicated to finding the best treatment for cancer patients through liquid biopsies and deep learning analytics. The team at CCG.ai were recognised with numerous accolades, including the Forbes 30 under 30 list and the Financial Times 100 Digital Champions, before exiting to Dante Labs in 2021.
Harry holds an MSci from The University of Nottingham, a DPhil from The University of Oxford, and completed postdoctoral research at The University of Cambridge, with academic work spanning human genetics, computational biology, and data-driven healthcare.
He will be leveraging his track record of success across entrepreneurship, industry, and academia to accelerate the development of next-generation Health Tech companies, with a particular focus on AI and digital biology. In his role, he will work closely with the portfolio companies to translate breakthrough science and research in Oxford into high-impact ventures.
Heather Roxborough, Senior Partner of Health Tech at OSE, said
“We’re delighted to welcome Harry to the team as our latest Entrepreneur in Residence. At OSE, we work closely with seasoned entrepreneurs like Harry to help them shape and scale their next venture. His deep expertise in building healthtech products and companies will be invaluable as we continue to turn Oxford’s world-class science into breakthrough startups that address the most urgent challenges in healthcare.”
Harry Clifford commented:
“We are at a pivotal moment in healthcare, where AI and digital biology have the potential to make a real difference in how we approach medicine. The Oxford ecosystem is rich with groundbreaking research, and OSE is uniquely positioned to turn these innovations into real-world solutions. I’m excited to join the team and help harness these technologies to build impactful ventures that will shape the future of healthcare."
OSE brings seasoned entrepreneurs in-house to help uncover the most promising scientific and technological innovations at Oxford and build them into world-leading businesses. This approach has led to the creation of pioneering Oxford spinouts, including neurology care platform Neu Health, photonic chip company Salience Labs, and neuromodulation company Amber Therapeutics.
OSE’s Health Tech team is helping build companies in AI imaging, big data analytics, digital pharma services, tech-enabled care delivery, smart diagnostics, next-generation medical devices and life science tools – impacting not only patients’ lives but entire healthcare systems.